ArticleCancer control : journal of the Moffitt Cancer Center

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.

Qiong Lyu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.